Kathleen N. Moore Discusses New PARP Inhibitors for Ovarian Cancer
March 15th 2017Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.
Watch
Ursula Matulonis Explains the Use of PARP Inhibitors for Ovarian Cancer
March 13th 2017Ursula Matulonis, M.D., professor of Medicine, Harvard Medical School, Medical Director of Gynecologic Oncology, Dana-Farber Cancer Institute, explains the benefits of PARP inhibitors for patients with ovarian cancer.
Watch
Elizabeth Swisher Discusses Rucaparib's Side Effects for Patients With Ovarian Cancer
March 13th 2017Elizabeth Swisher, M.D., professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the side effects of rucaparib in the ARIEL2 trial, for patients with relapsed, platinum-sensitive high-grade ovarian carcinoma.
Watch